Loading...
•
Mar 31, 2020
Ionis Q1 2020 Earnings Report
Ionis reported financial results for Q1 2020, highlighting commercial medicine performance and pipeline advancements.
Key Takeaways
Ionis Pharmaceuticals reported its Q1 2020 financial results, demonstrating strong performance in commercial medicines, particularly SPINRAZA, and advancements in its late-stage pipeline. The company reaffirmed its 2020 financial guidance, expecting to end the year meaningfully profitable, supported by commercial and R&D revenue. With a strong cash position of $2.4 billion, Ionis is well-capitalized to execute its strategic priorities.
Commercial revenue growth driven by SPINRAZA royalties, which increased by more than 10% compared to Q1 2019.
Product sales from TEGSEDI and WAYLIVRA more than doubled compared to Q1 2019.
R&D revenue included over $25 million from Ionis’ neurology disease franchise and $15 million from its cardiometabolic franchise.
The company reaffirmed its 2020 financial guidance, including ending 2020 meaningfully profitable.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
Ionis reaffirmed its 2020 financial guidance, including ending 2020 meaningfully profitable. The company expects results to be driven by continued commercial and R&D revenue.
Positive Outlook
- Initiate the Phase 3 study of AKCEA-APOCIII-LRx in patients with FCS
- Refile WAYLIVRA new drug application for U.S. marketing authorization
- File for WAYLIVRA marketing approval in Brazil with PTC Therapeutics
- Report clinical proof-of-concept results for four or more programs
- Advance five or more new medicines into development, including several Ionis-owned medicines
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties, including those related to the impact COVID-19 could have on our business
- Risks related to commercial products and medicines in the pipeline
- Risks inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics
- Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially
- You are cautioned not to rely on these forward-looking statements
Revenue & Expenses
Visualization of income flow from segment revenue to net income